STUDY/PROTOCOL TITLE AND PROTOCOL NUMBER: "A Phase II, Open-label Randomized Study of Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men with High Risk Prostate Cancer"; XL184-IST64
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Exelixis, Inc
Start Date
March 4, 2019
End Date
March 3, 2024
Administered By
Duke Cancer Institute
Awarded By
Exelixis, Inc
Start Date
March 4, 2019
End Date
March 3, 2024